PTC THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.85 USD | -3.17% |
|
+24.60% | +40.97% |
| May. 21 | Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating | MT |
| May. 20 | Raymond James Upgrades PTC Therapeutics to Market Perform From Underperform | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 749M | Sales 2025 * | 811M | Capitalization | 3.08B |
|---|---|---|---|---|---|
| Net income 2024 * | -400M | Net income 2025 * | -211M | EV / Sales 2024 * | 3.44 x |
| Net cash position 2024 * | 503M | Net cash position 2025 * | 424M | EV / Sales 2025 * | 3.27 x |
| P/E ratio 2024 * |
-7.72
x | P/E ratio 2025 * |
-13.8
x | Employees | 1,022 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on PTC Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -3.17% | ||
| 1 week | +24.60% | ||
| Current month | +20.84% | ||
| 1 month | +53.44% | ||
| 3 months | +49.77% | ||
| 6 months | +77.80% | ||
| Current year | +40.97% |
1 week
32.88
40.69
1 month
24.0040.69
Current year
23.5840.69
1 year
17.5359.75
3 years
17.5359.84
5 years
17.5370.82
10 years
4.0378.72
| Managers | Title | Age | Since |
|---|---|---|---|
Matthew Klein
CEO | Chief Executive Officer | 52 | 19-09-30 |
Pierre Gravier
DFI | Director of Finance/CFO | 39 | 23-07-12 |
Ellen Welch
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Glenn Steele
BRD | Director/Board Member | 79 | 15-06-14 |
| Chairman | 72 | 01-07-31 | |
David Southwell
BRD | Director/Board Member | 63 | 05-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.35% | 14 M€ | -2.76% | ||
| 0.36% | 0 M€ | 0.00% | - | |
| 0.25% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 38.85 | -3.17% | 1,296,199 |
| 24-05-20 | 40.12 | +21.23% | 2,858,822 |
| 24-05-17 | 33.1 | -2.75% | 646,621 |
| 24-05-16 | 34.03 | +1.10% | 546,624 |
| 24-05-15 | 33.66 | +7.95% | 573,656 |
Delayed Quote Nasdaq, May 21, 2024 at 04:00 pm EDT
More quotes
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Calendar
2024-06-18
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
38.85
USD
Average target price
35.91
USD
Spread / Average Target
-7.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.97% | 3.08B | |
| +8.63% | 115B | |
| +13.17% | 107B | |
| -12.76% | 22.31B | |
| -3.99% | 21.6B | |
| -7.19% | 18.23B | |
| -39.93% | 17.62B | |
| +6.67% | 14.26B | |
| +33.90% | 12.37B | |
| -28.60% | 8.28B |
- Stock Market
- Equities
- PTCT Stock